LPL Financial LLC Increases Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

LPL Financial LLC raised its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 24.7% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 26,386 shares of the company's stock after purchasing an additional 5,223 shares during the period. LPL Financial LLC owned 0.08% of TransMedics Group worth $1,645,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. National Bank of Canada FI grew its stake in TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company's stock valued at $65,000 after acquiring an additional 262 shares in the last quarter. Hager Investment Management Services LLC acquired a new position in shares of TransMedics Group during the 4th quarter worth approximately $33,000. Sachetta LLC purchased a new stake in shares of TransMedics Group in the fourth quarter valued at approximately $40,000. AlphaQuest LLC acquired a new stake in shares of TransMedics Group in the fourth quarter valued at approximately $52,000. Finally, Wilmington Savings Fund Society FSB purchased a new stake in TransMedics Group in the 3rd quarter valued at $149,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

TransMedics Group Trading Up 4.0 %

Shares of TMDX stock traded up $3.49 during trading hours on Tuesday, hitting $91.21. The company had a trading volume of 1,157,242 shares, compared to its average volume of 1,343,476. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The stock has a market capitalization of $3.09 billion, a PE ratio of 97.03 and a beta of 2.14. The company's fifty day moving average is $73.24 and its 200 day moving average is $78.72. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on TMDX shares. Canaccord Genuity Group reiterated a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, TransMedics Group presently has an average rating of "Moderate Buy" and a consensus price target of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.